|
Match
|
Document |
Document Title |
|
|
6432943 |
Method for treating sexual dysfunction
The invention provides a method for treating a sexual dysfunction comprising administering an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]be
nzodiazepine.
|
|
|
6426343 |
Preparation and use of a specific GABA-Aα5 receptor ligand for treatment of Alzheimer's disease
The present invention relates to a method of enhancing cognition without producing convulsions which method comprises administering to a subject in need thereof a cognition enhancing amount of a...
|
|
|
6423718 |
4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms...
|
|
|
6420357 |
Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
Disclosed are the compounds Asamarine A and B, novel cytotoxic diterpene-alkaloids, that have been isolated from the sponge Raspailia sp. The structure of these compounds have been established on...
|
|
|
6417184 |
Triple drug therapy for the treatment and prevention of acute or chronic pain
A triple drug therapy, pharmaceutical kit, composition, and method of treatment regimen utilized as a combination of effective amounts of an anxiolytic agent, centrally acting alpha antiadrenergic...
|
|
|
6413956 |
Substituted 4-oxo-quinoline-3-carboxamides
Disclosed are compounds of Formula I: or the pharmaceutically acceptable salts thereof where, R 1 , R 2 , and W are defined herein. These compounds are highly selective agonists, antagonists or...
|
|
|
6403651 |
Mediation of circadian rhythms
Method for mediating the effects of light on melatonin rhythmicity in mammals and a method of mediating circadian rhythms, effected by the administration of a compound or compounds effective at a...
|
|
|
6395729 |
Use of pyridazino&lsqb 4,5-b&rsqb indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors
Pyridazino[4,5-b]indole-1-acetamide derivatives for the prevention or treatment of diseases linked to the dysfunctioning of peripheral-type benzodiazepine receptors.
|
|
|
6395727 |
Method of treating Bulimia Nervosa and related eating disorders by administration of atypical antipsychotic medications
The invention relates to a method of treating non-psychotic disorders by administration of atypical antipsychotic medications, in particular, risperidone. More specifically, the invention relates...
|
|
|
6391871 |
Preventing neuronal degeneration in Alzheimer's disease
A method of treating Alzheimer's disease is disclosed, not just with palliatives, but in a manner that prevents the progressive degeneration caused by Alzheimer's disease. Certain types of...
|
|
|
6391873 |
Imidazodiazepine derivative
The present invention relates to compound 7-Chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5-m
ethyl-4,5-dihydro-imidazo[1,5-a][1,4]benzodiazepin-6-one (I) and to the use of the compound...
|
|
|
6365585 |
Phosphodiesterase IV-inhibiting diazepinoindoles
Metabolites of the products of formula (I) in which A and R are as defined in the description, which are phosphodiesterase 4 inhibitors.
|
|
|
6358944 |
Methods and compositions for treating generalized anxiety disorder
The present invention relates to methods and compositions comprising a very low dose of cyclobenzaprine or metabolite thereof for preventing and treating Generalized Anxiety Disorder. The present...
|
|
|
6352718 |
Vasopressin antagonist formulation and process
This invention provides novel formulations for N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)ylcarbonyl)
-3-chlorophenyl]-5-fluoro-2-methyl-benzamide, or a pharmaceutically acceptable salt...
|
|
|
6352984 |
Olanzapine-N-oxide compositions and methods
Methods and compositions are disclosed utilizing olanzapine-N-oxide for the treatment of psychosis in humans. Olanzapine-N-oxide exhibits a lessened liability toward drug-drug interactions than...
|
|
|
6348458 |
Polymorphic forms of olanzapine
The invention provides three new polymorphic forms of 2-methyl-4-[4-methyl-1-piperazinyl]-10H-thieno[2,3b][1,5]ben
zodiazepine (Olanzapine) (Formula A), the process for preparing the new polymorphs...
|
|
|
6346528 |
2-Hydroxymethylolanzapine compositions and methods
Methods and compositions are disclosed utilizing 2-hydroxymethylolanzapine for the treatment of psychosis in humans. 2-Hydroxymethylolanzapine exhibits a lessened liability toward drug-drug...
|
|
|
6344451 |
Pyrrolobenzodiazepine carboxyamide vasopressin agonists
The present invention provides compounds of the formula: wherein: X, Y and Z are independently selected from O, S, CH, CH 2 , N, or NR 4 ; W is moiety selected from (CH 2 ) n ; n=1-2; R 1 , R 2 ...
|
|
|
6329364 |
Crystalline form of dihydro-2,3-benzodiazepine derivative
A physical form of (R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-d
ioxolo[4,5-h][ 2,3]benzodiazepine having an X-ray powder diffraction pattern with d spacings at 12.78, 9.48, 8.99,...
|
|
|
6306847 |
Condensed purine derivatives
The present invention provides condensed purine derivatives or pharmacologically acceptable salts thereof exhibiting adenosine A 3 acceptor antagonising activity, and having an antiasthmatic...
|
|
|
6297234 |
Arylthiophene vasopressin agonists
The present invention provides compounds of the general formula: ##STR1## wherein Y is a moiety selected independently, from NH or --(CH 2 ) n -- wherein n is 1; m is an integer from 1 to 2;...
|
|
|
6294540 |
Carbocyclic nucleoside hemisulfate and its use in treating viral infections
The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2
-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
|
|
|
6288057 |
Physical form of dihydro-2,3-benzodiazepine derivative
A physical form of (R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-d
ioxolo[4,5-h][ 2,3]benzodiazepine having an X-ray powder diffraction pattern with d spacings at 10.61, 8.83, 6.78,...
|
|
|
6274633 |
NMDA antagonist
The present invention relates to the use of xenon as an NMDA antagonist. In particular, the invention relates to a method of treatment comprising modulating the activity of an NMDA receptor in a...
|
|
|
6274636 |
Method for treating a tic disorder
The invention provides a method for treating a tic disorder comprising administering an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]be
nzodiazepine.
|
|
|
6268360 |
1H-pyrido[2,3-b][1,5]benzodiazipine vasopressin agonists
The present invention provides compounds of the general formula: ##STR1## wherein Y is a moiety selected independently, from NH or --(CH 2 ) n -- wherein n is 1; m is an integer from 1 to 2; and...
|
|
|
6268359 |
Preventives or remedies for vision disorders
A pharmaceutical composition for preventing or treating visual function disorders caused by ocular circulatory disorders (for example, ocular hypertension and glaucoma) and visual function...
|
|
|
6251895 |
Olanzapine dihydrate D
The present invention provides the novel Dihydrate D 2-methyl-thieno-benzodiazepine and a formulation therefor.
|
|
|
6239130 |
Phosphodiesterase 4-inhibiting diazepinoindolones
##STR1## The present invention presents compounds that inhibit phosphodiesterase 4 having Formula (I). The present invention also provides methods of using the compounds of Formula (I) to prevent...
|
|
|
6235730 |
3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions comprising the same
3-piperidyl-4-oxoquinazoline derivatives are provided, which is represented by the formula (I): ##STR1## wherein R represents an amino group or a cyclic amino group such as dibenzoazepine, each of...
|
|
|
6225306 |
Biphenyl derivatives and drug composition
A biphenyl derivative represented by the following general formula (1) and a pharmaceutically acceptable salt thereof: ##STR1## [In the formula (1), A represents a single bond, --CH 2 --, --CO--,...
|
|
|
6221861 |
Reducing pyrophosphate deposition with calcium antagonists
This invention provides a method of treating an animal with pyrophosphate gout or osteoarthritis comprising administering an effective amount of a calcium antagonist, thereby reducing calcium...
|
|
|
6218387 |
Vitronectin receptor anatagonists, their preparation and their use
The present invention relates to compounds of the formula I, A--B--D--E--F--G (I) in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use...
|
|
|
6214837 |
Pharmaceutical composition for the treatment of so-called restless legs
A pharmaceutical composition for the treatment of so-called restless legs is disclosed, which composition comprises a combination of: A) quinine, preferably, in the form of a pharmaceutically...
|
|
|
6197764 |
Clozapine compositions and uses thereof
The invention provides compositions that include conjugates of a fatty acid molecule, preferably cis-docosahexaenoic acid, and clozapine. The conjugates are useful in treating psychological...
|
|
|
6194407 |
Tricyclic pyrido vasopressin agonists
The present invention provides compounds of the general formula: ##STR1## wherein W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilizing these compounds...
|
|
|
6174881 |
Hydroxymethylimidazodiazepines and their esters
The invention is concerned with hydroxymethyl-imidazodiazepines and their esters of general formula I. These compounds can be used as anxiolytic and/or anticonvulsant and/or muscle relaxant and/or...
|
|
|
6169084 |
2-methyl-thieno-benzodiazepine formulation
The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel...
|
|
|
6159963 |
Method for treating substance abuse
The invention provides a method for treating substance abuse comprising administering an effective amount of olanzapine or pharmaceutically acceptable salt thereof to a patient in need thereof.
|
|
|
6150353 |
Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
This application relates to a combination of the antidepressant mirtazapine and an antipsychotic agent such as haloperidol for the treatment of psychotic disorders.
|
|
|
6147072 |
Combination therapy for treatment of psychoses
The invention relates to a method of treating psychosis, acute mania, mild anxiety states or depression in combination with psychotic episodes by administering to a patient a combination of an...
|
|
|
6140322 |
Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
There are provided novel compounds of formula (I) ##STR1## wherein X, R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification and optical isomers and racemates thereof and...
|
|
|
6136801 |
Therapeutic agent with quantitative consumption marker
Quantitative compliance markers and associated methods for monitoring patient compliance with medication prescriptions associated with compliance markers have been found to eliminate the need for...
|
|
|
6127363 |
Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
A method is provided for treating erectile dysfunction, e.g., vasculogenic erectile dysfunction such as vasculogenic impotence. The method involves the administration of a Type IV phosphodiesterase...
|
|
|
6124346 |
Estrogen agonist/antagonists treatment of atherosclerosis
A method of treating atherosclerosis, independent of lipid lowering, in mammals, including humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque....
|
|
|
6114326 |
Use of cabergoline in the treatment of restless legs syndrome
The present invention provides for the use of cabergoline and other agents for the treatment of restless legs syndrome (RLS).
|
|
|
6114370 |
Amnesic sedation composition and method of administering same
This invention relates to a pharmaceutical amnesic sedation composition for administering to a subject comprising an effective of: (i) a benzodiazepine derivative, (ii) a phenanthrene derivative,...
|
|
|
6103715 |
Dopamine receptor ligands
Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered,...
|
|
|
6103734 |
Drug combination as a medicament to suppress the dependence of individuals to opiates
Combination of chemical compounds used as a medicament intended to suppress the dependence of individuals to opioids, the combination comprising a laxative or enema of irrigation, repeated doses of...
|
|
|
6100256 |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
The present invention provides a method for the treatment or prevention of schizophrenic disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical...
|